| 比伐卢定抗凝作用的研究进展 |
| |
| 引用本文： | 白元,秦永文.比伐卢定抗凝作用的研究进展[J].药学服务与研究,2006,6(6):446-449. |
| |
| 作者姓名： | 白元 秦永文 |
| |
| 作者单位： | 第二军医大学长海医院心血管内科,上海,200433 |
| |
| 摘 要： | FDA在2000年批准了一种新的直接凝血酶抑制剂比伐卢定应用于临床，该药是水蛭素的类似物，它通过抑制凝血酶的活性位点而起效。国外将其与其他常用的抗凝药进行了比较研究，认为比伐卢定可以作为普通肝素和血小板糖蛋白Ⅱb／Ⅲa拮抗剂的替代药物应用于非高危患者的经皮冠脉介入治疗。
|
| 关 键 词： | 比伐卢定 抗凝药 综述 |
| 文章编号： | 1671-2838(2006)06-0446-04 |
| 收稿时间： | 04 5 2006 12:00AM |
| 修稿时间： | 07 26 2006 12:00AM |
The advance in research on anticoagulative effect of bivalirudin |
| |
| BAI Yuan,QIN Yong-wen.The advance in research on anticoagulative effect of bivalirudin[J].Pharmaceutical Care and Research,2006,6(6):446-449. |
| |
| Authors: | BAI Yuan QIN Yong-wen |
| |
| Institution: | Department of Cardiovasology, Changhai Hospital, Second Military Medical University, Shanghai 200433,China |
| |
| Abstract: | Bivalirudin, as a new direct inhibitor of thrombin, was approved by US Food and Drug Administration in 2000. It is an analogue of hirudin that can inhibit the active site of thrombin. After compared with other anticoagulants, many studies suggested that bivalirudin could substitute for heparin or glycoprotein (GP) II b/ III a inhibitors in non-high-risk patients undergoing percutaneous coronary intervention. |
| |
| Keywords: | bivalirudin anticoagulants review |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
